Asymchem Laboratories (Tianjin) completed a $125 million IPO in Shenzhen. Asymchem is contract manufacturer of APIs, cGMP intermediates and finished drugs, all from a severak manufacturing facilities in China. Most of the proceeds will be used to build its R&D facilities and additional manufacturing facilities in Tianjin, which is also the company’s headquarters.
